Peptides researched for
Alzheimer's disease
4 peptides · 6 studies
What people research this for
An Alzheimer's diagnosis sends families looking for anything that might help. A handful of peptides have been studied in this area, mostly in the lab or in early studies. None is an approved Alzheimer's treatment.
Researched for
- Memory loss in Alzheimer's
- Protecting brain cells
- Mild cognitive impairment
What the studies say so far
Cerebrolysin has the longest record, with about 30 years of clinical use reviewed, including a study that paired it with the Alzheimer's drug donepezil and tracked biological markers. The quality of those trials varies a lot. Dihexa and related compounds have mostly been tested in experimental models of Alzheimer's. Humanin work is lab research on how brain cells die. Semax has a brain imaging study, which is a long way from a treatment trial. Overall the research is early and the results are mixed.
Peptides studied
Each peptide below has been studied in this area. The label shows how far that research has gone.
Dihexa
Early lab and animal researchResearch review · 2 studies
Study note. Small-molecule Ang IV analogs (including Dihexa) are reviewed for AD models, not approved Alzheimer drugs.
- The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. (opens in a new tab)
Wright JW, Kawas LH, Harding JW · Progress in neurobiology · 2015 · PubMed
- Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. (opens in a new tab)
Ho JK, Nation DA · Neuroscience and biobehavioral reviews · 2018 · PubMed
- The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. (opens in a new tab)
Cerebrolysin
Mixed resultsResearch review · 2 studies
Study note. 30-year clinical-use review plus NDEV biomarker study with Cerebrolysin/donepezil, evidence quality varies by trial.
- Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. (opens in a new tab)
Gavrilova SI, Alvarez A · Medicinal research reviews · 2021 · PubMed
- Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil. (opens in a new tab)
Alvarez XA, Winston CN, Barlow JW · Journal of Alzheimer's disease : JAD · 2022 · PubMed
- Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. (opens in a new tab)
Humanin
Early lab and animal researchAnimal study · 1 study
Study note. Humanin mechanistic paper shows JNK-pathway neuroprotection in AD-related cell death models.
- SH3-binding protein 5 mediates the neuroprotective effect of the secreted bioactive peptide humanin by inhibiting c-Jun NH2-terminal kinase. (opens in a new tab)
Takeshita Y, Hashimoto Y, Nawa M · The Journal of biological chemistry · 2013 · PubMed
- SH3-binding protein 5 mediates the neuroprotective effect of the secreted bioactive peptide humanin by inhibiting c-Jun NH2-terminal kinase. (opens in a new tab)
Semax
Small early studies in peopleObservational study in people · 1 study
Study note. Semax connectomic imaging work is not equivalent to disease-modifying Alzheimer therapy.
- Functional Connectomic Approach to Studying Selank and Semax Effects. (opens in a new tab)
Panikratova YR, Lebedeva IS, Sokolov OY · Doklady biological sciences · 2020 · PubMed
- Functional Connectomic Approach to Studying Selank and Semax Effects. (opens in a new tab)
Look this up in the PeptIQ app
The app has the same research and sources, next to the tools you use to track your own protocol.
